ADAP - 3 Top Biotech Stocks to Buy in February
Despite mounting political pressure to drastically lower prescription drug prices in the United States, the biotech industry as a whole has performed quite well during the opening weeks of 2020. The long and short of it is that investors are still fairly optimistic about biotech's long-term prospects, thanks to the rapid pace of innovation, the aging global population, and the steady march toward increased access to healthcare services around the world.
Which biotech stocks are worth buying this month? Adaptimmune Therapeutics (NASDAQ: ADAP), Applied Therapeutics (NASDAQ: APLT), and Kiniksa Pharmaceuticals (NASDAQ: KNSA) are three small-cap drugmakers with plenty of room to run in February and beyond. Here's what you need to know about these promising growth plays right now.
Image source: Getty Images.